Publicaciones en colaboración con investigadores/as de Pfizer (United States) (31)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2020

  1. Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization

    Archives of Pathology and Laboratory Medicine, Vol. 144, Núm. 6, pp. 735-741

2018

  1. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: Results from the ENIGMA Schizophrenia DTI Working Group

    Molecular Psychiatry, Vol. 23, Núm. 5, pp. 1261-1269

2017

  1. Prevalence of Insomnia and Associated Factors in Outpatients With Generalized Anxiety Disorder Treated in Psychiatric Clinics

    Behavioral Sleep Medicine, Vol. 15, Núm. 6, pp. 491-501

2016

  1. An integrated analysis of the efficacy and safety of Desvenlafaxine in the treatment of major depressive disorder

    International Clinical Psychopharmacology, Vol. 31, Núm. 3, pp. 134-146

2015

  1. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

    Annals of General Psychiatry, Vol. 14, Núm. 1

  2. Inflammation in schizophrenia: A question of balance

    Neuroscience and Biobehavioral Reviews, Vol. 55, pp. 612-626

  3. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

    Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340

  4. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma

    Molecular Cancer Therapeutics, Vol. 14, Núm. 7, pp. 1548-1558

  5. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms

    International Clinical Psychopharmacology, Vol. 30, Núm. 5, pp. 265-271

2014

  1. Oxidative/nitrosative stress in psychiatric disorders: Are we there yet?

    Schizophrenia Bulletin, Vol. 40, Núm. 5, pp. 960-962

2013

  1. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

    Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174

  2. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

  3. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain

    Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996

2012

  1. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study

    Clinical Practice and Epidemiology in Mental Health, Vol. 8, pp. 158-168

  2. Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice

    European Psychiatry, Vol. 27, Núm. 4, pp. 301-307

  3. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain

    ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168

2011

  1. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use

    European Addiction Research, Vol. 17, Núm. 5, pp. 262-270

  2. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

    European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875

2010

  1. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

    Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109